ArticleNeurogastroenterology and motility2025
Abnormal Homeostasis in the Redox State and Related Signaling Pathways, in Irritable Bowel Syndrome.
Article in Neurogastroenterology and motility, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Abnormal Homeostasis in the Redox State and Related Signaling Pathways, in Irritable Bowel Syndrome.Neurogastroenterology and motility · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIBS is multifactorial; however, elucidating its underlying mechanisms is crucial for advancing in its diagnosis and management.
aimsEvaluate molecular processes related to oxidative stress (OS) and inflammation in IBS and its subtypes.
methodsThirty Rome III-IBS outpatients and 30 controls were studied for OS biomarkers, including malondialdehyde (MDA), protein carbonyls (PC), reduced glutathione (GSH), and oxidized glutathione (GSSG). Also, serum interleukins (IL-10, IL-4, TNF-α, IL-6), and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), nuclear factor erythroid 2-related factor 2 (Nrf2), and nicotinamide-adenine-dinucleotide phosphate (NADPH) catalytic subunit gp91
resultsIn IBS vs. controls there were higher MDA: 4.44 ± 1.76 vs. 2.42 ± 0.5 nmol/mg/protein (p < 0.01); GSSG: 57.17 ± 17.49 vs. 42.73 ± 14.26 μM (p < 0.01); and lower GSH: 26.17 ± 12.36 vs. 38.47 ± 16.71 μM (p < 0.01). Also, an imbalance in pro- and anti-inflammatory interleukins (p < 0.01); and higher NF-κB: 5.33 ± 3.39 vs. 3.08 ± 1.19 (p = 0.01); gp91
conclusionsThe data demonstrate an alteration in the homeostasis of the cellular redox state in IBS. Also, in IBS-D, the antioxidant effect counteracts the low-grade inflammation, whereas in IBS-C, it is mainly driven by interleukins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.